<DOC>
	<DOC>NCT01509105</DOC>
	<brief_summary>It is an observational multi-center study to assess the safety profile of Prevenar13 used among Korean children in the routine clinical setting following a licensure and introduction of the vaccine. This study is designed to fulfill regulatory requirement for any new drug authorized by KFDA.</brief_summary>
	<brief_title>Prevenar13 Post Market Surveillance</brief_title>
	<detailed_description>non-randomization, non-probability sampling</detailed_description>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants and children aged 6 weeks to 5 years, whose legally authorized representatives of patients agree to provide written informed consent form (data privacy statement). Infants and children who are not indicated and/or contraindicated for the Prevenar13 usage will not be included.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>